


## PHARMACEUTICAL 2022

## Biostax Corp. Rank 431 of 466









## PHARMACEUTICAL 2022

## Biostax Corp. Rank 431 of 466



The relative strengths and weaknesses of Biostax Corp. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Biostax Corp. compared to the market average is the variable Expenses, increasing the Economic Capital Ratio by 44% points. The greatest weakness of Biostax Corp. is the variable Liabilities, Current, reducing the Economic Capital Ratio by 300% points.

The company's Economic Capital Ratio, given in the ranking table, is -203%, being 281% points below the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	3,139
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	11,087
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	0
Property and Equipment	0
Research and Development	153
Selling, General and Administrative Expense	586

Output Variable	Value in 1000 USD
Assets	3,139
Liabilities	11,087
Expenses	738
Revenues	0
Stockholders Equity	-7,948
Net Income	-738
Comprehensive Net Income	-738
Economic Capital Ratio	-203%

